AML1/RUNX1 Phosphorylation by Cyclin-dependent Kinases Regulates the Degradation of AML1/RUNX1 by the Anaphase-promoting Complex

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2006 Oct 4

PMID 17015473

Citations 46

Authors

Joseph R Biggs

Luke F Peterson

Youhong Zhang

Andrew S Kraft

Dong-Er Zhang

Affiliations

Soon will be listed here.

Abstract

AML1 (RUNX1) regulates hematopoiesis, angiogenesis, muscle function, and neurogenesis. Previous studies have shown that phosphorylation of AML1, particularly at serines 276 and 303, affects its transcriptional activation. Here, we report that phosphorylation of AML1 serines 276 and 303 can be blocked in vivo by inhibitors of the cyclin-dependent kinases (CDKs) Cdk1 and Cdk2. Furthermore, these residues can be phosphorylated in vitro by purified Cdk1/cyclin B and Cdk2/cyclin A. Mutant AML1 protein which cannot be phosphorylated at these sites (AML1-4A) is more stable than wild-type AML1. AML-4A is resistant to degradation mediated by Cdc20, one of the substrate-targeting subunits of the anaphase-promoting complex (APC). However, Cdh1, another targeting subunit used by the APC, can mediate the degradation of AML1-4A. A phospho-mimic protein, AML1-4D, can be targeted by Cdc20 or Cdh1. These observations suggest that both Cdc20 and Cdh1 can target AML1 for degradation by the APC but that AML1 phosphorylation may affect degradation mediated by Cdc20-APC to a greater degree.

Citing Articles

Application of a high-throughput swarm-based deep neural network Algorithm reveals SPAG5 downregulation as a potential therapeutic target in adult AML.

Ajonu C, Grundy R, Ball G, Zafeiris D Funct Integr Genomics. 2025; 25(1):8.

PMID: 39762615 PMC: 11703901. DOI: 10.1007/s10142-024-01514-9.

Cyclin-dependent kinases (CDKs) are key genes regulating early development of Neptunea arthritica cumingii: evidence from comparative transcriptome and proteome analyses.

Lv F, Ge X, Chang Y, Hao Z BMC Genomics. 2024; 25(1):1221.

PMID: 39701993 PMC: 11660575. DOI: 10.1186/s12864-024-10970-3.

CDK9 phosphorylates RUNX1 to promote megakaryocytic fate in megakaryocytic-erythroid progenitors.

Kwon N, Lu Y, Thompson E, Mancuso R, Wang L, Zhang P Blood. 2024; 144(17):1800-1812.

PMID: 39102635 PMC: 11530366. DOI: 10.1182/blood.2024023963.

Pharmacological inhibition of RAS overcomes FLT3 inhibitor resistance in FLT3-ITD+ AML through AP-1 and RUNX1.

Coleman D, Keane P, Chin P, Ames L, Kellaway S, Blair H iScience. 2024; 27(4):109576.

PMID: 38638836 PMC: 11024925. DOI: 10.1016/j.isci.2024.109576.

CDK6 inhibits de novo lipogenesis in white adipose tissues but not in the liver.

Hu A, Li W, Dinh C, Zhang Y, Hu J, Daniele S Nat Commun. 2024; 15(1):1091.

PMID: 38316780 PMC: 10844593. DOI: 10.1038/s41467-024-45294-z.

References

Peterson L, Boyapati A, Ranganathan V, Iwama A, Tenen D, Tsai S . The hematopoietic transcription factor AML1 (RUNX1) is negatively regulated by the cell cycle protein cyclin D3. Mol Cell Biol. 2005; 25(23):10205-19. PMC: 1291252. DOI: 10.1128/MCB.25.23.10205-10219.2005. View

Mulloy J, Cammenga J, Mackenzie K, Berguido F, Moore M, Nimer S . The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood. 2002; 99(1):15-23. DOI: 10.1182/blood.v99.1.15. View

Wotton S, Blyth K, Kilbey A, Jenkins A, Terry A, Bernardin-Fried F . RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene. 2004; 23(32):5476-86. DOI: 10.1038/sj.onc.1207729. View

Murray A . Recycling the cell cycle: cyclins revisited. Cell. 2004; 116(2):221-34. DOI: 10.1016/s0092-8674(03)01080-8. View

Wee H, Huang G, Shigesada K, Ito Y . Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms. EMBO Rep. 2002; 3(10):967-74. PMC: 1307622. DOI: 10.1093/embo-reports/kvf193. View

Biggs J, Zhang Y, Peterson L, Garcia M, Zhang D, Kraft A . Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association. Mol Cancer Res. 2005; 3(7):391-401. DOI: 10.1158/1541-7786.MCR-04-0184. View

Burns C, Traver D, Mayhall E, Shepard J, Zon L . Hematopoietic stem cell fate is established by the Notch-Runx pathway. Genes Dev. 2005; 19(19):2331-42. PMC: 1240042. DOI: 10.1101/gad.1337005. View

Okuda T, van Deursen J, Hiebert S, Grosveld G, Downing J . AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84(2):321-30. DOI: 10.1016/s0092-8674(00)80986-1. View

Wang Q, Stacy T, Binder M, Marin-Padilla M, Sharpe A, Speck N . Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc Natl Acad Sci U S A. 1996; 93(8):3444-9. PMC: 39628. DOI: 10.1073/pnas.93.8.3444. View

10.

Strom D, Nip J, Westendorf J, Linggi B, Lutterbach B, Downing J . Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem. 2000; 275(5):3438-45. DOI: 10.1074/jbc.275.5.3438. View

11.

Erickson P, Dessev G, Lasher R, Philips G, Robinson M, Drabkin H . ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease. Blood. 1996; 88(5):1813-23. View

12.

Tanaka T, Kurokawa M, Ueki K, Tanaka K, Imai Y, Mitani K . The extracellular signal-regulated kinase pathway phosphorylates AML1, an acute myeloid leukemia gene product, and potentially regulates its transactivation ability. Mol Cell Biol. 1996; 16(7):3967-79. PMC: 231393. DOI: 10.1128/MCB.16.7.3967. View

13.

Theriault F, Nuthall H, Dong Z, Lo R, Barnabe-Heider F, Miller F . Role for Runx1 in the proliferation and neuronal differentiation of selected progenitor cells in the mammalian nervous system. J Neurosci. 2005; 25(8):2050-61. PMC: 6726063. DOI: 10.1523/JNEUROSCI.5108-04.2005. View

14.

Bain J, McLauchlan H, Elliott M, Cohen P . The specificities of protein kinase inhibitors: an update. Biochem J. 2003; 371(Pt 1):199-204. PMC: 1223271. DOI: 10.1042/BJ20021535. View

15.

Levanon D, Goldstein R, Bernstein Y, Tang H, Goldenberg D, Stifani S . Transcriptional repression by AML1 and LEF-1 is mediated by the TLE/Groucho corepressors. Proc Natl Acad Sci U S A. 1998; 95(20):11590-5. PMC: 21685. DOI: 10.1073/pnas.95.20.11590. View

16.

Chen C, Broom D, Liu Y, de Nooij J, Li Z, Cen C . Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain. Neuron. 2006; 49(3):365-77. DOI: 10.1016/j.neuron.2005.10.036. View

17.

Lutterbach B, Westendorf J, Linggi B, Isaac S, Seto E, Hiebert S . A mechanism of repression by acute myeloid leukemia-1, the target of multiple chromosomal translocations in acute leukemia. J Biol Chem. 2000; 275(1):651-6. DOI: 10.1074/jbc.275.1.651. View

18.

Major M, Lepe R, Costa R . Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation-dependent recruitment of p300/CBP coactivators. Mol Cell Biol. 2004; 24(7):2649-61. PMC: 371108. DOI: 10.1128/MCB.24.7.2649-2661.2004. View

19.

Ubersax J, Woodbury E, Quang P, Paraz M, Blethrow J, Shah K . Targets of the cyclin-dependent kinase Cdk1. Nature. 2003; 425(6960):859-64. DOI: 10.1038/nature02062. View

20.

Iwatsuki K, Tanaka K, Kaneko T, Kazama R, Okamoto S, Nakayama Y . Runx1 promotes angiogenesis by downregulation of insulin-like growth factor-binding protein-3. Oncogene. 2004; 24(7):1129-37. DOI: 10.1038/sj.onc.1208287. View